Pharma Pulse 11/11/24: The Importance of Improving DE&I in Clinical Trials, Financial Toxicity About More Than Just Affording Treatment & more

Peer Exchange: The Importance of Improving DE&I in Clinical Trials

In this roundtable discussion, industry experts gathered to address the state of achieving greater diversity in clinical research. The group highlighted a variety of topics including current challenges they are seeing, the use of technology, and more.

Moderated by Otis Johnson, PhD, MPA Co-Founder & Principal Consultant, Trial Equity, the panel featured key insights from Sophia McLeod, Sr. Director, Government Relations, ACRO; Erin Stern, PharmD, Research Support Pharmacist, Mayo Clinic; and Caitlin Brown, PharmD, Neurocritical Care and Emergency Medicine Clinical Pharmacist, Mayo Clinic.

Why Financial Toxicity is About More Than Just Affording Treatment

The idea of financial toxicity combines the physical stress of having a disease like breast cancer with concerns about affording treatment, according to Laila Gharzai, M.D., LLM, from the Department of Radiation Oncology at Northwestern University.

U.S. Agency Warns Employees About Phone Use Amid Ongoing China Hack

Consumer Financial Protection Bureau tells workers to reduce use of cellphones for work due to risk from China-linked telecom intrusion.

No-Cost Heart & Kidney Health Screening Available on Nov. 11-14 in Houston

Care Access is bringing its Heart & Kidney Health Screening initiative to Houston, Texas. This health screening aims to raise awareness and provide testing for certain health risk factors, including a dangerous type of cholesterol known as lipoprotein(a), or Lp(a), which impacts one in five people and significantly increases the risk of heart disease and stroke.

Russo Partners on LinkedIn

Check out this article from Pharmaceutical Executive. The global radiopharmaceutical market is on track to grow from $9.07 billion in 2023 to an impressive $26.51 billion by 2031, fueled by advancements in diagnostic and therapeutic applications for conditions like cancer and Alzheimer’s disease.

Established markets in North America continue to benefit from robust infrastructure and innovation in theranostics and AI-driven personalized medicine. This evolution is a game-changer in healthcare, promising enhanced treatment precision and expanded patient access worldwide.

Read the full article:https://bit.ly/3O14fcZ

#Radiopharmaceuticals #HealthcareInnovation #Theranostics

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs